edits.seer.internal.rules.IFN6660.xml Maven / Gradle / Ivy
Go to download
Show more of this group Show more artifacts with this name
Show all versions of validation-edits-seer Show documentation
Show all versions of validation-edits-seer Show documentation
Java implemenation of the SEER edits.
<rule id="IFN6660" name="Recurrence Type--1st, CoC Flag (SEER)" tag="N6660" java-path="lines.line" category="inter-field" depends="Year_of_Diagnosis">
<expression><![CDATA[if (line.dateOfDiagnosisYear == null || line.dateOfDiagnosisYear < '2021' || line.cocAccreditedFlag != '1')
return true
if (line.registryId == '0000001565' && line.dateOfDiagnosisYear < '2023')
return true
if (line.registryId == '0000001566' && line.dateOfDiagnosisYear < '2022')
return true
return ((List)Context.IFN6660_List).contains(line.recurrenceType1st)]]></expression>
<message>Not a valid value for Recurrence Type--1st</message>
<description><![CDATA[The edit is skipped for any of the following conditions:
a. Date of Diagnosis is blank (unknown), invalid, or pre-2021.
b. CoC Accredited Flag is not = 1
c. Registry ID = 0000001565 (Illinois) and Year of Diagnosis < 2023
d. Registry ID = 0000001566 (Texas) and Year of Diagnosis < 2022
This data item is required by SEER only for analytic cases from CoC-accredited facilities.
Must be a valid code for Recurrence Type--1st (00,04,06,10,13-17,20-22,25-27,30,36,40,46,51-60,62,70,88,99).
00 Patient became disease-free after treatment and has not had recurrence
04 In situ recurrence of invasive tumor
06 In situ recurrence of in situ tumor
10 Local recurrence, insufficient information to code to 13-17
13 Local recurrene of invasive tumor
14 Trocar recurrene of invasive tumor
15 Both local and trocar recurrence of invasive tumor
16 Local recurrence of in situ tumor, NOS
17 Both local and trocar recurrence of in situ tumor
20 Regional recurrence, insufficient information to code to 21-27
21 Recurrence of invasive tumor in adjacent organ(s) only
22 Recurrence of invasive tumor in regional lymph nodes only
25 Recurrence of invasive tumor in adjacent tissue or organ(s) and in regional nodes at same time
26 Regional recurrence of in situ tumor NOS
27 Recurrence of in situ tumor in adjacent tissue or organ(s) and in regional lymph nodes at same time
30 Both regional recurrence of invasive tumor in adjacent tissue or organ(s) and/or regional lymph odes and local
and/or trocar
recurrence
36 Both regional recurrence of in situ tumor in adjacent tissue or organ(s) and/or regional lymph odes and local
and/or trocar
recurrence
40 Distant recurrence to site not listed in 46-62 or insufficient information to code to 46-62
46 Distant recurrence of in situ tumor
51 Distant recurrence of invasive tumor in peritoneum only.
52 Distant recurrence of invasive tumor in lung only.
53 Distant recurrence of invasive tumor in pleura only
54 Distant recurrence of invasive tumor in liver only
55 Distant recurrence of invasive tumor in bones only
56 Distant recurrence of invasive tumor in CNS only.
57 Distant recurrence of invasive tumor in skin only.
58 Distant recurrence of invasive tumor in lymph node only.
59 Distant systemic recurrence of invasive tumor only
60 Distant recurrence of invasive tumor in single distant site and local, trocar and/or regional recurrence
62 Distant recurrence of invasive tumor in multiple sites
70 Since diagnosis patient has never been disease-free.
88 Disease has recurred but type of recurrence unknown
99 Unknown whether disease has recurred or if patient was ever disease-free]]></description>
<history>
<event version="SE22-022-01" user="beverung" date="2022-03-04" ref="68896">Edit Created</event>
<event version="SE22-022-04" user="secristc" date="2022-04-29" ref="68980">Changed skip condition to pre 2021</event>
<event version="SE22-022-08" user="beverung" date="2022-06-16" ref="69010">Added skip conditions for IL and TX.</event>
</history>
</rule>